Table 1 Cohort characteristics

From: MAP2 immunoreactivity deficit is conserved across the cerebral cortex within individuals with schizophrenia

 

NPC

Schizophrenia (SZ)

n

20

20

Age, mean ± SD

47.7 ± 9.5

45.4 ± 9.3

Sex, M/F

14/6

14/6

pH, mean ± SD

6.7 ± 0.2

6.5 ± 0.3

PMI, hours ± SD

15.5 ± 5.7

14.5 ± 6.1

Storage time, months ± SD

114.1 ± 42.8

113.6 ± 48.9

Nicotine ATOD, Y/N

 

14/4

Antipsychotic ATOD, Y/N

 

18/2

Antidepressant ATOD, Y/N

 

11/9

Benzodiazepine/VPA ATOD, Y/N

 

5/15

Asphyxiation, Y/N

3/17

8/12

Hypoxia, Y/N

4/16

4/16

Ischemia, Y/N

0/20

5/15

AHI, Y/N

6/14

12/8

  1. Diagnostic groups showed no significant differences in age (t37 = 0.68, p = 0.50), PMI (t37 = 0.55, p = 0.58), storage time (t37 = 0.14, p = 0.89), pH (t34 = 1.79, p = 0.08), nor in frequency of asphyxiation (X2[1,N = 20] = 3.13, p = 0.08), ischemia (X2[1,N = 20] = 3.66, p = 0.06), hypoxia, or the presence of one or more of these risk variables (AHI; see text) (X2[1,N = 20] = 3.64, p = 0.06). Additional cohort details can be found in Supplementary Table 1
  2. SD standard deviation, PMI postmortem interval, M male, F female, ATOD at time of death, AHI asphyxiation/hypoxia/ischemia (see text)
Back to article page